98%
921
2 minutes
20
Higher-order exceptional point (EP) geometries, comprising lines, rings, or surfaces formed by EPs, have garnered significant attention due to their rich topological properties and potential sensing applications. However, constructing such geometries remains challenging, as it requires additional degrees of freedom in the Hamiltonian's parameter space or higher symmetry levels, particularly in discrete systems. Here, by introducing controlled asymmetric couplings, we investigate the symmetry and exceptional lines (ELs) in non-Hermitian diamond photonic lattices. The second- and third-order ELs emerge when parity-time and pseudo-chirality symmetries are satisfied. These lines can be dynamically tuned by adjusting non-reciprocal coupling strength and inter-cell coupling ratios. Our work provides a platform for exploring higher-order EP-related phenomena, such as enhanced sensitivity in topological sensors and chiral mode switching in discrete non-Hermitian systems.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1364/OL.571684 | DOI Listing |
Channels (Austin)
December 2025
Biorheology Research Laboratory, Faculty of Health, Griffith University, Gold Coast, Australia.
The hallmarks of mechanosensitive ion channels have been observed for half a century in various cell lines, although their mechanisms and molecular identities remained unknown until recently. Identification of the bona fide mammalian mechanosensory Piezo channels resulted in an explosion of research exploring the translation of mechanical cues into biochemical signals and dynamic cell morphology responses. One of the Piezo isoforms - Piezo1 - is integral in the erythrocyte (red blood cell; RBC) membrane.
View Article and Find Full Text PDFEur J Haematol
September 2025
Department of Hematology-Oncology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have revolutionized the approach and management of relapsed/refractory multiple myeloma (RRMM), and as of 2025, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are the only BCMA-targeted CAR T-cell therapies approved by the FDA. Exceptional responses were demonstrated for heavily pretreated patients in the KarMMa-1 trial, reporting a 73% overall response rate (ORR) and 98% in the CARTITUDE-1 trial. Furthermore, both therapies show a significant improvement in progression-free survival (PFS) compared to standard regimens when administered in earlier lines.
View Article and Find Full Text PDFBioorg Chem
August 2025
Wenzhou Medical University, Wenzhou 325035, PR China; Zhejiang Cancer Hospital, Hangzhou 310022, PR China. Electronic address:
Transcriptional enhanced associate domain (TEAD), overexpressed in hepatocellular carcinoma (HCC) and inversely correlated to prognosis, has emerged as a promising target for HCC therapy. To date, no small-molecule inhibitors targeting TEAD have been reported for HCC treatment. In this study, a bioinformatic analysis has been performed and has demonstrated that TEAD is a promising target for therapeutic intervention in HCC.
View Article and Find Full Text PDFChem Res Toxicol
September 2025
Department of Physiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina 45110, Greece.
Graphene-based nanomaterials have transformed biomedical applications due to their exceptional physicochemical properties, and nitrogen (N)-doping further enhances the electrocatalytic activity of graphene. Driven by the demand for safer and more sustainable nanomaterials, in this work, we compared eco-friendly produced - doped graphene (bD) with conventionally synthesized - doped graphene (cD) in three different cell lines. Across all cell types and assays, cD was more toxic than bD.
View Article and Find Full Text PDFJ Mater Chem B
September 2025
Sardar Vallabhbhai National Institute of Technology, Ichchanath, Surat-395 007, Gujarat, India.
Cancer is widely recognized as one of the most critical public health challenges, transcending economic boundaries and impacting populations across all socioeconomic strata. Developing effective cancer therapies is significantly hindered by challenges such as chemotherapy-related side effects, drug resistance, and tumor metastasis, which contribute to poor prognoses for many patients. In this context, inorganic drugs, particularly polyoxomolybdate-based inorganic-organic hybrids, are emerging as promising candidates for future metallodrugs.
View Article and Find Full Text PDF